Absence of Glucocorticoids Concomitant With Avacopan and Subsequent Liver Injury in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Avacopan, a C5a receptor (C5aR) inhibitor, has emerged as a novel treatment for antineutrophil cytoplasmic antibody-associated vasculitis (AAV), providing an alternative to glucocorticoids (GCs). 1 Despite its promising potential, severe liver dysfunction associated with avacopan has been reported in Japan. 2,3 .